Wave life sciences posts q3 loss per share of $1.48

Wave life sciences reports third quarter 2019 financial results and provides business update.wave life sciences ltd - topline data from precision-hd2 clinical trial expected by year-end.wave life sciences ltd - qtrly loss per share $1.48.wave life sciences ltd - as of september 30, 2019, wave had $209.0 million in cash and cash equivalents as compared to $174.8 million as of december 31, 2018.
WVE Ratings Summary
WVE Quant Ranking